




RealRate

PHARMACEUTICAL 2021

Albireo Pharma INC
Rank 204 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Albireo Pharma INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Albireo Pharma INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 263%, being 6.8% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	261,865
Cost of Goods Sold	0
Intangible Assets	17,260
Liabilities, Current	25,282
Liabilities, Non-Current	3,579
Other Assets	6,004
Other Compr. Net Income	-15,064
Other Expenses	-14,646
Other Liabilities	75,515
Other Net Income	-11,362
Other Revenues	8,308
Property and Equipment	478
Research and Development	76,777
Selling, General and Administrative Expense	42,448

Output Variable	Value in 1000 USD
Assets	285,607
Liabilities	104,376
Expenses	104,579
Revenues	8,308
Stockholders Equity	181,231
Net Income	-107,633
Comprehensive Net Income	-115,165
BaseVar	264,648
ECR before LimitedLiability	144%
Economic Capital Ratio	263%